These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 25936329

  • 1. Actual situation of lipoprotein apheresis in Saxony in 2013.
    Emmrich U, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
    [Abstract] [Full Text] [Related]

  • 2. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S, Fischer S, Weiss N, Julius U.
    Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
    [Abstract] [Full Text] [Related]

  • 3. Current situation of lipoprotein apheresis in Saxony.
    Julius U, Taseva K, Fischer S, Passauer J, Bornstein SR.
    Atheroscler Suppl; 2013 Jan; 14(1):51-5. PubMed ID: 23357141
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [Abstract] [Full Text] [Related]

  • 5. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
    [Abstract] [Full Text] [Related]

  • 6. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
    Julius U, Tselmin S, Schatz U, Fischer S, Birkenfeld AL, Bornstein SR.
    Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
    [Abstract] [Full Text] [Related]

  • 7. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
    Schatz U, Tselmin S, Müller G, Julius U, Hohenstein B, Fischer S, Bornstein SR.
    Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
    [Abstract] [Full Text] [Related]

  • 8. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.
    Sampietro T, Sbrana F, Bigazzi F, Ripoli A, Dal Pino B, Pasanisi EM, Petersen C, Coceani M, Luciani R, Pianelli M.
    Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336
    [Abstract] [Full Text] [Related]

  • 9. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
    [Abstract] [Full Text] [Related]

  • 10. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, Waldmann E, Parhofer KG, Moriarty PM.
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
    Heigl F, Pflederer T, Klingel R, Hettich R, Lotz N, Reeg H, Schettler VJJ, Roeseler E, Grützmacher P, Hohenstein B, Julius U.
    Atheroscler Suppl; 2019 Dec; 40():23-29. PubMed ID: 31818446
    [Abstract] [Full Text] [Related]

  • 12. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR, Julius U.
    Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
    [Abstract] [Full Text] [Related]

  • 13. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, Pro(a)LiFe Study Group*.
    Circulation; 2013 Dec 17; 128(24):2567-76. PubMed ID: 24056686
    [Abstract] [Full Text] [Related]

  • 14. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Scientific Board of GLAR for the German Apheresis Working Group.
    Atheroscler Suppl; 2017 Nov 17; 30():50-55. PubMed ID: 29096861
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R, Heibges A, Fassbender C.
    Atheroscler Suppl; 2015 May 17; 18():35-40. PubMed ID: 25936302
    [Abstract] [Full Text] [Related]

  • 16. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
    Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R, Pro(a)LiFe-Study Group.
    Arterioscler Thromb Vasc Biol; 2016 Sep 17; 36(9):2019-27. PubMed ID: 27417585
    [Abstract] [Full Text] [Related]

  • 17. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.
    Dittrich-Riediger J, Schatz U, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May 17; 18():45-52. PubMed ID: 25936304
    [Abstract] [Full Text] [Related]

  • 18. Factors inducing cardiovascular events in patients treated by lipoprotein apheresis.
    Taseva K, Fischer S, Passauer J, Weiss N, Bornstein SR, Julius U.
    Atheroscler Suppl; 2013 Jan 17; 14(1):45-50. PubMed ID: 23357140
    [Abstract] [Full Text] [Related]

  • 19. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.
    Atheroscler Suppl; 2017 Nov 17; 30():180-186. PubMed ID: 29096835
    [Abstract] [Full Text] [Related]

  • 20. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
    Tselmin S, Müller G, Schatz U, Julius U, Bornstein SR, Hohenstein B.
    Atheroscler Suppl; 2017 Nov 17; 30():209-216. PubMed ID: 29096840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.